Case series reports reversible tardive dyskinesia due to aripiprazole in women, suggesting potential for recovery upon discontinuation.
Tardive dyskinesia (TD) is a slow-onset, hyperkinetic movement disorder involving repetitive involuntary movements. It is classified as a medication-induced movement disorder that occurs in association with the use of dopamine-blocking agents–most commonly, antipsychotics. It is classically understood as an unremitting process, with a few cases of reversible conditions and uncertain remission rates. Aripiprazole possesses a distinct and unique mechanism that decreases its risk compared to other antipsychotics. In this case series, we discuss three cases involving Saudi women who developed aripiprazole-induced TD; notably, all cases remitted upon aripiprazole discontinuation or dose reduction without utilizing other forms of treatment. The current literature remains limited in describing aripiprazole-induced TD, lacking a clear understanding of the development of TD following aripiprazole administration, the determined remission rate, and definite management.
No takes yet. Share an insight, caveat, or question.
Alshahrani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: